Literature DB >> 27696465

Characteristics of carcinogenic human papillomavirus infection in Suzhou: Epidemiology, vaccine evaluation, and associated diseases.

Wen Jing Li1, Hong Xing Xu1, Zhao Hua Chen1, Wei Dong Xu1, Yuan Jian Wu1.   

Abstract

Human papillomavirus infection is a major health problem and caused substantial benign and malignancy diseases among female and male worldwide. We aim to investigate the epidemiology of high-risk human papillomavirus (HR-HPV) and related diseases in Suzhou population. As well as evaluating the potential benefit of a nine-valent HPV vaccine (regardless of HPV-6 and -11) in Suzhou. A total of 40,108 people aged 13-89 years were retrospectively examined by database retrieval from 2010 to 2015. Thirteen genotypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 66) of HR-HPV were detected using Tellgenplex™ xMAP™ HPV DNA Test assay. The overall prevalence of HR-HPV was 21.1%, the female and male account for 96.4% and 3.6%, respectively. The infection rate among male (25.6%, 367/1,432) was significantly higher than that among female (20.9%, 8,100/38,676), X2  = 17.341 (P < 0.001), with OR = 1.293, 95% CI (1.146-1.460). The five most frequent HR-HPV genotypes were HPV-16 (5.12%), -52 (5.07%), -58 (3.02%), -39 (2.00%), and -18 (1.74%). HR-HPV infection rate was peak in person aged <20 years, and second higher in person aged 51-60 years. Infection modes as HPV-16, -18, -31, -33, -45, -52, -58 alone or mixed accounted for 63.2%. The top three prevalent diseases in HR-HPV infected women were cervicitis, vaginitis, and cervical lesions, and in men were verruca, urethritis, and balanitis, respectively. This is the first study to demonstrate HPV infection status in Suzhou population. Both women and men had a large burden of HPV infection. The nine-valent HPV prophylactic vaccines may potentially prevent 63.2% HR-HPV infection in Suzhou. J. Med. Virol. 89:895-901, 2017.
© 2016 Wiley Periodicals, Inc. © 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  genotype; high risk (HR); human papillomavirus (HPV); prevalence; vaccine

Mesh:

Substances:

Year:  2016        PMID: 27696465     DOI: 10.1002/jmv.24700

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  4 in total

1.  Rising Mortality Rate of Cervical Cancer in Younger Women in Urban China.

Authors:  Min Wei; Wei Zhou; Yongyi Bi; Hong Wang; Yu Liu; Zhi-Jiang Zhang
Journal:  J Gen Intern Med       Date:  2018-11-27       Impact factor: 5.128

2.  Human Papillomavirus Type 16 E1 Mutations Associated with Cervical Cancer in a Han Chinese Population.

Authors:  Yueting Yao; Zhiling Yan; Shuying Dai; Chuanyin Li; Longyu Yang; Shuyuan Liu; Xinwen Zhang; Li Shi; Yufeng Yao
Journal:  Int J Med Sci       Date:  2019-06-24       Impact factor: 3.738

3.  Association of Human Papillomavirus Type 16 Long Control Region Variations with Cervical Cancer in a Han Chinese Population.

Authors:  Shuying Dai; Chuanyin Li; Zhiling Yan; Ziyun Zhou; Xia Wang; Jun Wang; Le Sun; Li Shi; Yufeng Yao
Journal:  Int J Med Sci       Date:  2020-03-26       Impact factor: 3.738

4.  Characteristics of human papillomavirus infection among women with cervical cytological abnormalities in the Zhoupu District, Shanghai City, China, 2014-2019.

Authors:  Ping Li; Qing Liu; Wei Li; Zhou Liu; Baoling Xing; Suqin Wu; Zhaoli Zhou; Liping Sun; He Ren; Hengfeng Li; Huaping Li
Journal:  Virol J       Date:  2021-03-08       Impact factor: 4.099

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.